£810 / $1295 / €985
Corruption will continue to affect Vietnam's pharmaceutical and healthcare business environment and potentially delay the introduction of universal healthcare coverage for its people. While corruption is a clear downside risk, we maintain that the sector still offers strong growth opportunities for foreign investors.
Headline Expenditure Projections
Pharmaceuticals : VND50,081bn (US$2.43bn) in 2011 to VND61,910bn (US$2.94bn) in 2012; +23.6% in local currency terms and +21.4% in US dollar terms.
Healthcare: VND157, 666bn (US$7.63bn) in 2011 to VND181,879bn (US$8.65bn) in 2012; +15.4% in local currency terms and +13.3% in US dollar terms.
Medical devices: VND15,137bn (US$733mn) in 2011 to VND17,029bn (US$810mn) in 2012; +12.5% in local currency terms and +10.5% in US dollar terms.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.